Chimerix
oral brain penetrant antagonist agonist second generation designed to expand to new indications efficacy in cell culture and central nervous system and other tumor models oral dose trials ongoing in cancers response reported by investigator in early dose cohort for a patient in recurrent non | Chimerix
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
31 of 43
Similar slides by Chimerix
See diffirences between slides (animation)
Investor Presentation
May 2023
oral brain penetrant antagonist agonist | Chimerix
Investor Presentation
March 2023
oral brain penetrant antagonist agonist | Chimerix
Related slides by other companies
Genprex
Investor Presentation
October 2022
| Genprex
Ocuphire Pharma
Investor Presentation
May 2023
profile overview well tolerated oral dose up to day twice daily dosing progression of diabetic minimal ocular side effects ire cine | Ocuphire Pharma
Genprex
Investor Presentation
November 2024
| Genprex
Erasca
Investor Presentation
January 2024
dose cohorts | Erasca
Other recent decks by Chimerix
See all presentations (6 decks)
Investor Presentation
May 2023
Investor Presentation
March 2023
Results
March 2022
Investor Conference
November 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights